Advances and challenges in precision imaging

Hedvig Hricak; Marius E Mayerhoefer; Ken Herrmann; Jason S Lewis; Martin G Pomper; Christopher P Hess; Katrine Riklund; Andrew M Scott; Ralph Weissleder

doi:10.1016/S1470-2045(24)00395-4

Advances and challenges in precision imaging

Lancet Oncol. 2025 Jan;26(1):e34-e45. doi: 10.1016/S1470-2045(24)00395-4.

Authors

Hedvig Hricak¹, Marius E Mayerhoefer², Ken Herrmann³, Jason S Lewis⁴, Martin G Pomper⁵, Christopher P Hess⁶, Katrine Riklund⁷, Andrew M Scott⁸, Ralph Weissleder⁹

Affiliations

¹ Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
³ Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
⁴ Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology and Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA.
⁵ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁶ Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA.
⁷ Department of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
⁸ Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.
⁹ Department of Radiology and Center for Systems Biology, Massachusetts General Brigham, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].

PMID: 39756454
DOI: 10.1016/S1470-2045(24)00395-4

Abstract

Technological innovations in genomics and related fields have facilitated large sequencing efforts, supported new biological discoveries in cancer, and spawned an era of liquid biopsy biomarkers. Despite these advances, precision oncology has practical constraints, partly related to cancer's biological diversity and spatial and temporal complexity. Advanced imaging technologies are being developed to address some of the current limitations in early detection, treatment selection and planning, drug delivery, and therapeutic response, as well as difficulties posed by drug resistance, drug toxicity, disease monitoring, and metastatic evolution. We discuss key areas of advanced imaging for improving cancer outcomes and survival. Finally, we discuss practical challenges to the broader adoption of precision imaging in the clinic and the need for a robust translational infrastructure.

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics
Diagnostic Imaging / methods
Humans
Neoplasms* / diagnostic imaging
Neoplasms* / genetics
Precision Medicine*

Substances

Biomarkers, Tumor